RT Journal Article
T1 Polypharmacy and Drug–Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study
A1 López-Centeno, Beatriz
A1 Badenes-Olmedo, Carlos
A1 Mataix-Sanjuan, Ángel
A1 McAllister, Katie
A1 Bellón, José M
A1 Gibbons, Sara
A1 Balsalobre, Pascual
A1 Pérez-Latorre, Leire
A1 Benedí González, Juana María
A1 Marzolini, Catia
A1 Aranguren-Oyarzábal, Ainhoa
A1 Khoo, Saye
A1 Calvo-Alcántara, , María J
A1 Berenguer, Juan
AB BackgroundDrug-drug interactions (DDIs) that involve antiretrovirals (ARVs) tend to cause harm if unrecognized, especially in the context of comorbidity and polypharmacy.MethodsA linkage was established between the drug dispensing registry of Madrid and the Liverpool human immunodeficiency virus (HIV) DDI database (January 2017-June 2017). Polypharmacy was defined as the use of ≥5 non-HIV medications, and DDIs were classified by a traffic-light ranking for severity.ResultsA total of 22 945 people living with HIV (PLWH) and 6 613 506 individuals without HIV had received medications. ARV regimens were predominantly based on integrase inhibitors (51.96%). Polypharmacy was higher in PLWH (32.94%) than individuals without HIV (22.16%; P < .001); this difference was consistently observed across all age strata except for individuals ≥75 years. Polypharmacy was more common in women than men in both PLWH and individuals without HIV. The prevalence of contraindicated combinations involving ARVs was 3.18%. Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest risk for red-flag DDI, and the use of raltegravir- or dolutegravir-based antiretroviral therapy was associated with an adjusted odds ratio of 0.72 (95% confidence interval, .60-.88; P = .001) for red-flag DDI.ConclusionsPolypharmacy was more frequent among PLWH across all age groups except those aged ≥75 years and was more common in women. The detection of contraindicated medications in PLWH suggests a likely disconnect between hospital and community prescriptions. Switching to alternative unboosted integrase regimens should be considered for patients with risk of harm from DDIs.
PB Oxford Academic
SN 1058-4838
YR 2019
FD 2019-08-20
LK https://hdl.handle.net/20.500.14352/93089
UL https://hdl.handle.net/20.500.14352/93089
LA eng
NO López-Centeno B, Badenes-Olmedo C  Mataix-Sanjuan Á, McAllister K, Bellón JM, Gibbons S, Balsalobre P, Pérez-Latorre L, Benedí J, Marzolini C, Aranguren-Oyarzábal A, Khoo S, Calvo-Alcántara MJ, Berenguer J.  Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. linical Infectious Diseases, 2020 uly 15; 71(2): 353–62.
NO Merck Sharp & Dohme Investigator Studies Program
NO Plan Nacional R + D + I
NO Instituto de Salud Carlos III-Subdirección General de Evaluación
NO Fondo Europeo de Desarrollo Regiona
DS Docta Complutense
RD 21 abr 2025